Pharming Group (PHGUF) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Pharming Group has received U.K. marketing authorization for Joenja® (leniolisib), a novel treatment for activated phosphoinositide 3-kinase delta syndrome in patients aged 12 and above. This marks the first U.K. approval for a medication specifically targeting APDS, a rare immunodeficiency disease, and represents the third country approval for Pharming’s treatment. The company’s CEO highlights this as a significant step towards their goal of being a leading global rare disease company.
For further insights into PHGUF stock, check out TipRanks’ Stock Analysis page.
